Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism

Area of Science:

• Oncology
• Medicinal Chemistry
• Computational Biology

Background:

• Human Epidermal growth factor Receptor 1 (HER1) and HER2 are frequently overexpressed in human tumors.
• Overexpression of HER1 and HER2 drives cellular proliferation, making them significant targets in anticancer therapy.
• Dual HER1/HER2 inhibitors are approved and marketed for cancer treatment.

Purpose of the Study:

• To identify novel compounds with anticancer activity targeting the kinase domains of HER1 and HER2.
• To utilize a combined virtual screening approach for drug discovery.
• To optimize lead compounds for enhanced potency.

Main Methods:

• Virtual screening of compound libraries against HER1 and HER2 kinase domains.
• Identification of hit compounds with sub- or low-micromolar activity in cell-based assays.
• Iterative design and synthesis of compounds to improve activity.

Main Results:

• Identification of 6 hit compounds with sub- or low-micromolar activity.
• Subsequent optimization led to the synthesis of a compound with nanomolar activity.
• Demonstrated potential of virtual screening in discovering targeted anticancer agents.

Conclusions:

• The study successfully identified novel anticancer compounds targeting HER1 and HER2.
• Virtual screening combined with medicinal chemistry optimization is an effective strategy for developing potent anticancer agents.
• The synthesized compound with nanomolar activity warrants further investigation for therapeutic applications.